Epigral Limited has informed the Exchange regarding a press release dated May 05, 2025, titled "Press Release for Audited Financial Results Q4 & FY2025".
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.2 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Epigral Limited (formerly Meghmani Finechem) posted its highest-ever annual revenue of ₹2,565 crore in FY2025, up 33% year-on-year, driven by 11% volume growth led by Derivatives & Specialty products. FY2025 PAT jumped 82% to ₹357 crore, with EBITDA up 48% to ₹711 crore and EBITDA margin expanding to 28% from 25%. In Q4FY25, revenue grew 20% to ₹631 crore, EBITDA rose 12% to ₹173 crore, and PAT was up 13% at ₹87 crore. The balance sheet strengthened with ROCE improving to 25% (from 18%) and Net Debt/EBITDA falling sharply to 0.7x (from 2.0x). Credit rating was upgraded to Crisil AA from AA-, the company raised ₹333 crore via QIP, spent ₹195 crore on capex, and announced doubling of CPVC Resin and Epichlorohydrin capacities. Total dividend for FY25 is ₹6 per share (60% on face value of ₹10).
Strong all-round results with broad-based revenue and profit growth, expanding margins, deleveraging, and a credit rating upgrade signal robust financial health. Capacity expansion, QIP proceeds, and higher dividend are positive for shareholders, though realizations dipped for most products in FY25.